Early breast cancer (eBC): PERJETA is indicated for use in combination with trastuzumab and chemotherapy in:1

• the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence

• the adjuvant treatment of adult patients with HER2-positive eBC at high risk of recurrence

   

Metastatic breast cancer (mBC): PERJETA is indicated for use in combination with trastuzumab and docetaxel in adult patients with  
HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy
for their metastatic disease1

Perjeta Efficacy

View the effect that PERJETA‑trastuzumab plus chemotherapy had on outcomes in patients with eBC and mBC

eBC (neoadjuvant)

eBC (adjuvant)

mBC

Mechanism of Action

Perjeta Safety

Learn about the generally manageable safety profile of PERJETA‑trastuzumab plus chemotherapy

Across indications

eBC (neoadjuvant) safety

eBC (adjuvant) safety

mBC safety

Perjeta Dosing

See practical guidance on how to dose and administer PERJETA‑trastuzumab plus chemotherapy in different indications

Posology & modifications

Preparation & administration

Duration of treatment

 

 

 

Perjeta Resources

View a range of practical and educational resources

Expert opinions

Downloadable presentation slides

Downloadable booklet

Early breast cancer (eBC) (neoadjuvant)

National Institute for Health and Care Excellence (NICE) recommendation

  • PERJETA, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with HER2‑positive breast cancer; that is, in patients with HER2‑positive, locally advanced, inflammatory or early‑stage breast cancer at high risk of recurrence2

Scottish Medicines Consortium (SMC) recommendation

  • PERJETA is accepted for use within NHS Scotland in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2‑positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence3


Early breast cancer (eBC) (adjuvant)

NICE recommendation

  • PERJETA, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of HER2‑positive early stage breast cancer in adults, only if they have lymph node‑positive disease4


Metastatic breast cancer (mBC)

NICE recommendation

  • PERJETA, in combination with trastuzumab and docetaxel, is recommended, within its marketing authorisation, for treating HER2‑positive metastatic or locally recurrent unresectable breast cancer, in adults who have not had previous anti‑HER2 therapy or chemotherapy for their metastatic disease5

SMC recommendation

  • PERJETA is accepted for use within NHS Scotland in combination with trastuzumab and docetaxel, in adult patients with HER2‑positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti‑HER2 therapy or chemotherapy for their metastatic disease6

 

eBC, early breast cancer; mBC, metastatic breast cancer; NICE, National Institute for Health and Care Excellence;
SMC, Scottish Medicines Consortium.

Reference:

  1. PERJETA Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. Pertuzumab for the neoadjuvant treatment of HER2‑positive breast cancer (TA424). December 2016.
  3. Scottish Medicines Consortium. SMC2119. December 2018.
  4. National Institute for Health and Care Excellence. Pertuzumab for adjuvant treatment of HER2‑positive early stage breast cancer (TA569). March 2019.
  5. National Institute for Health and Care Excellence. Pertuzumab with trastuzumab and docetaxel for treating HER2‑positive breast cancer (TA509). March 2018.
  6. Scottish Medicines Consortium. SMC2120. January 2019.

 

 

M-GB-00000631.

Date of preparation: July 2020.